Search Results - Endovascular Today

evt | Article | June 2021

An Interview With Sahil A. Parikh, MD

Dr. Parikh shares his pathway to interventional cardiology and vascular medicine, predictions on the role of sirolimus in peripheral artery disease, insights on thromboembolism during the COVID-19 era, and his inspiration for dedicating his career to teaching and training.

evt | Article | November 2023

Roundtable Discussion: Paclitaxel Safety and What We Have Learned

With William A. Gray, MD; Sahil A. Parikh, MD; and Peter A. Schneider, MD

evt | Article | June 2025 Supplement

Is It Time to Shed the Lead?

Why an innovative, inclusive radiation protection strategy for the cath lab must be prioritized.

By Sahil A. Parikh, MD

evt | Article | September 2021

The Near Future of Antiproliferative Therapy for Femoropopliteal Disease

Discussing the methods of vascular drug delivery in the treatment of SFA lesions.

By Sahil A. Parikh, MD, and Navneet Sharma, MD

evt | Article | August 2018

Left Superficial Femoral Artery Occlusion in a Patient With an Aortobifemoral Graft

Moderator: Ehrin J. Armstrong, MD
Panel: Steve Henao, MD, FACC, FACS; Sahil A. Parikh, MD, FACC, FSCAI; and Saher Sabri, MD, FSIR

evt | Article | November 2021

The State of Transradial Access for Lower Extremity Intervention

Reviewing the relevance, benefits, challenges, and needs for further innovation of radial access for lower extremity intervention.

By Sahil A. Parikh, MD; Joseph J. Ricotta, MD, MS, DFSVS, FACS; and Ahmed Ghamraoui, DO

evt | Article | September 2020

The Role of the BioMimics 3D® Stent in FemPop Intervention: A Look Ahead at Use in the United States

Thomas Zeller, MD, talks with Sahil A. Parikh, MD; Miguel Montero-Baker, MD; and Robert E. Beasley, MD, about how the recent availability of the BioMimics 3D system in the United States will impact their clinical practice.

evt | Article | January 2020

Lower Extremity Revascularization: Recent Past and Future Directions

Commentary on five key articles related to peripheral artery disease published over the past year, top headlines, and critical questions to be answered for the future.

By Joseph J. Ingrassia, MD; Matthew T. Finn, MD; and Sahil A. Parikh, MD

evt | Article | September 2024

Drug Delivery From ATK to BTK: What Is on the Horizon?

Experts discuss differences in drug delivery between ATK and BTK, the future of sirolimus-coated balloons, device innovation in the infrapopliteal arteries, where drug-eluting bioresorbable scaffolds fit into the BTK algorithm, and the most significant unmet needs.

With moderator Ramon L. Varcoe, MBBS, MS, FRACS, PhD, MMed(ClinEpi), and panelists Marianne Brodmann, MD; Osamu Iida, MD, PhD; Sahil A. Parikh, MD; and Peter A. Schneider, MD

evt | News | October 6, 2021

Veryan’s BioMimics 3D Shows Similar 2-Year Patency in Treatment of Claudicants and CLTI Patients

October 6, 2021—The VIVA Foundation announced that the BioMimics 3D nitinol stent (Veryan Medical), which features a three-dimensional (3D) helical centerline, was evaluated in the MIMICS-3D European registry to treat patients with longer, more complex lesions than previously studied.

evt | News | August 27, 2019

Computational Model Suggests a New Paradigm for Accelerated Treatment Optimization With Paclitaxel Devices

August 28, 2019—CBSET announced that its scientists have published data and analyses that provide critical insights into the interplay between target anatomy and device attributes in determining balloon- and stent-based paclitaxel retention in healthy and diseased arteries.

evt | News | November 14, 2023

Recor Medical’s Paradise uRDN System Launched in United States

November 14, 2023—Recor Medical, Inc. and its parent company, Otsuka Medical Devices Co., Ltd., have announced the first commercial uses of Recor’s Paradise ultrasound renal denervation (uRDN) system for the treatment of hypertension.

evt | Article | September 2024

Evolving PAD Approaches

By Peter A. Schneider, MD

evt | News | April 29, 2024

Abbott’s Esprit BTK Everolimus-Eluting Resorbable Scaffold Gains FDA Approval

April 29, 2024—Abbott announced that the FDA has approved the transcatheter Esprit BTK everolimus-eluting resorbable scaffold system for the treatment of patients with below-the-knee (BTK) chronic limb-threatening ischemia (CLTI).

evt | News | May 3, 2024

Data From REAL-PE Analysis Show Disparities in Catheter-Based PE Treatment

May 3, 2024—New data from the REAL-PE analysis, which investigated catheter-based pulmonary embolism (PE) treatment, showed that women and Black patients were less frequently treated with minimally invasive therapy compared to men or non-Black patients.

evt | Article | September 2021

Femoropopliteal Disease: Challenges and Progress

By Marianne Brodmann, MD, and Ehrin J. Armstrong, MD, MSc, MAS, FACC, FSCAI, FSVM

evt | News | June 18, 2019

TCT Conference and VEITHsymposium Form Alliance

June 19, 2019—The Cardiovascular Research Foundation (CRF) and the VEITHsymposium announced an alliance between CRF's Transcatheter Cardiovascular Therapeutics (TCT) annual scientific symposium and the VEITHsymposium.

evt | News | June 1, 2023

Penumbra Launches Lightning Bolt 7 Computer-Aided Arterial Thrombectomy System

June 1, 2023—Penumbra, Inc. announced the launch of the Lightning Bolt 7 arterial thrombectomy system.

evt | News | September 30, 2020

CBSET Preclinical Study Shows Balloon-Based Drug Delivery Is Critically Dependent on Coating Micromorphology

September 30, 2020—CBSET Inc., a not-for-profit translational research institute, announced the publication of a preclinical study, “Balloon-based drug coating delivery to the artery wall is dictated by coating micro-morphology and angioplasty pressure gradients,” by Abraham R. Tzafriri , PhD, et al online ahead of print in the Journal of Biomaterials.

evt | Article | June 2021

Dialysis Access and the Real-World Proving Ground

By Bart Dolmatch, MD, and Neghae Mawla, MD